Asia
Shenzhen Chipscreen Biosciences Gets Macau Approval for Diabetes Drug
Shenzhen Chipscreen Biosciences (SHA:688321) obtained the marketing approval of Macau's drug regulator for its chiglitazar sodium tablets.The drug, sold under the trade names Shuangluoping and Bilessglu, is indicated for type two diabetes as both monotherapy and in combination with metformin, according to a Friday filing with the Shanghai bourse.Shares of the drug developer closed 2% lower Friday.
SHA:688321
